A continuum is something that keeps going—such as a circle, a spiral, or in this case, the connection between neuroscience, inflammation and immunology (NI&I).
We are pioneering new therapies for conditions at the intersection of NI&I. People with these diseases often face limited options. We are primarily developing treatments with clinically validated biological targets to address these serious diseases—altering the pathways that drive them.
Development of a potential best-in-class therapy in idiopathic pulmonary fibrosis (IPF), chronic pain and progressive multiple sclerosis (PrMS).
Development of a potential first-in-class therapy for major depressive disorder (MDD) and relapsing-remitting multiple sclerosis (RRMS) in collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
Patients and their families are our true center—every one of our innovations, decisions and milestones is guided by their needs.